“…With respect to laboratory values, vital signs, and ECG findings, there were no pronounced differences between palonosetron and older 5-HT 3 RAs. The studies analyzed here did not thoroughly evaluate QTc measures; however, recent studies in patients with cancer 17,18 and a thorough QTc study in healthy subjects that used a positive control (ie, moxifloxacin) 16 demonstrated no significant QTc changes associated with palonosetron. This is in contrast to evidence of significant dose-related QTc prolongation with ondansetron, which led to the removal of the 32-mg single dose from its label, 30 and an increased risk of cardiac arrhythmias with IV dolasetron, which is no longer recommended.…”